First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic,nonsquamous non–small cell lung cancer: A United States–based cost-effectiveness analysis 期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic,nonsquamous non–small cell lung cancer: A United States–based cost-effectiveness analysis

摘要：